• Explore /
  • Poster
  • / Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with >5 years of follow-up in patients with advanced renal cell carcinoma (aRCC).

Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with >5 years of follow-up in patients with advanced renal cell carcinoma (aRCC).

Abstract Poster

Authors

null

Robert J. Motzer

Memorial Sloan Kettering Cancer Center, New York, NY

Robert J. Motzer , Scott S. Tykodi , Bernard Escudier , Stephane Oudard , Hans J. Hammers , David F. McDermott , Saby George , Daniel Castellano , Toni K. Choueiri , Ajjai Shivaram Alva , Martin Eduardo Richardet , Elizabeth R. Plimack , Sandy Srinivas , Giuseppe Procopio , Frede Donskov , Howard Gurney , Yoshihiko Tomita , M. Brent McHenry , Shruti Shally Saggi , Nizar M. Tannir

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer

Track

Renal Cell Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT01668784

Citation

J Clin Oncol 38, 2020 (suppl 6; abstr 617)

Abstract #

617

Poster Bd #

D3

Abstract Disclosures

Similar Posters

First Author: Saby George

First Author: Ruchit Shah

First Author: Robert J. Motzer

First Author: Antoine Thiery-Vuillemin